Did COVID-19 contribute to the Advancement of humanity?

Consider remote work, learning, and education, as well as the recent developments in AI and machine learning. What are COVID-19's obvious effects?  The explanation provided does not imply that COVID-19 was a positive thing or that it did not cause harm. Conversely, I shall analyze the advantages of the COVID-19 era and experience in a completely different way. In this synopsis, I examine how COVID-19 has affected technology use and the efficient application of science on an individual, communal, regional, and global level.

Despite the rapid development of medical countermeasures during the worldwide COVID-19 pandemic response, high-income nations and low- and middle-income countries (LMICs) did not completely avoid morbidity and mortality. The entire human and financial cost of the COVID-19 pandemic has not yet been realized as new variations and post-infection conditions continue to surface and impact health systems and economies. It is now imperative that we take note of these shortcomings and establish more fair and inclusive frameworks for both epidemic prevention and response.

Rebuilding trust, investing in robust local manufacturing capacity, supply chains, regulatory frameworks, and giving LMIC voices a central place in decision-making processes will all contribute to ensuring that the region is ready for any threats in the future. It's time to stop talking about learning and applying lessons and start acting to create a future that is more resilient.

Covid 19 and technology use

Businesses and educational institutions are moving toward work-from-home policies as a result of increased digitalization. Blockchain technology is going to grow in importance and will require regulatory and design studies. The number of gig workers and the gig economy is projected to rise, posing issues with presenteeism, job overload, motivation, and teamwork in addition to task allocation. The growing prevalence of digital media will make workplace monitoring and issues related to technostress more visible.

 

Both online fraud and security management research are expected to increase. After the epidemic, controlling the internet—a vital resource—will be essential. On the plus side, rising savings and investment should correspond with rising operating costs.

 

In the health sector

One of the most important ways to stop the virus's spread was to use digital technology for assistance, medical advice, healthcare service delivery, and virus tracking.

Even though digital technology was first used in healthcare services decades ago in the form of telehealth or remote healthcare services, the pandemic has significantly increased the use and development of this technology as a crucial component in mitigating the disease and breaking the cycle of disease transmission. Both hard and soft advancements are present in digital health solutions. Medical device use from a distance is referred to as "hard health innovation," whereas patient education and device operation and monitoring are considered "soft health innovations."

 

The terms used to describe the digital technology utilized to deliver healthcare during the pandemic are indicative of the technology's origins, modes, or ancillary services. For instance, the phrase "telehealth" refers to phone or online services that offer regular check-ups, such as recording disease symptoms and monitoring vital signs, to confirmed COVID-19 patients. Another example is the electronic intensive care unit (eICU), where a live video camera is used by the healthcare provider to support other healthcare providers and keep an eye on ICU patients in a different hospital. 

In order to slow the spread of COVID-19 and offer healthcare, digital technologies were adopted and implemented more quickly as a result of the pandemic.

 As a result, it's clear that digital technology applications in healthcare delivery are popular and could eventually replace traditional methods of providing treatment. More knowledge is required even though the usage of digital health technologies is enhancing healthcare services.

It's crucial to take a pause to consider the following queries:

Which digital technologies have been employed to reduce the spread of the virus during the COVID-19 pandemic? How much have uses of digital technology contributed to slowing down the COVID-19 pandemic?Which COVID-19 pandemic-related enablers and impediments have improved the usability of digital technologies?

Are there any lessons that can be transferred to other sectors from the Covid-19 era?

A few of these developments have applications in the fields of trade, commerce, and education. Humanity was driven to the breaking point during the worldwide epidemic, and swift action was taken from many fronts. This had enormous impact on food production, as evidenced by the current food crisis plaguing humanity. Actually, food prices have doubled and in some cases tripled globally.  To make sure that animals and crops were watched over, new technologies were improved. There are new online and remote research methodologies available nowadays. This has greatly elevated agricultural research.

In the education sector, the technological divide during the pandemic set nations apart as some In some nations, school closures lasted longer than 18 months. Remote learning was introduced in the technologically advanced states, allowing the students to continue their education. Consequently, this gap causes a split and a leap within the 2020–2021 academic cohorts. Despite the difficulties encountered, mankind was able to advance, and valuable lessons were learned from the event. For example, there is now proof that students can complete their degrees more quickly and remotely. This implies that students can complete a year's worth of coursework in six months. Additionally, it implies that teachers can make 50% more money and that the expense of schooling in the areas of boarding and facility use can be decreased. All of this was noted throughout the pandemic.

Politicians may labor for less money while maintaining the same level of performance, and government executives may reduce their salaries while boosting the economy. That being said, there is room for disagreement because every state has had a different experience. Executive teams faced severe operational and financial difficulties as a result of the COVID-19 global pandemic. Companies responded to financial strains by reducing employee salaries, implementing furloughs, and initiating layoffs. CEOs quickly discovered that they were being targeted by corporations as well, particularly with regard to pay.

Businesses had to weigh the risks of keeping CEO compensation high in the face of economic uncertainty against the possible backlash from shareholders and other stakeholders if they reduced financial incentives at a time when even more was expected of them.

There is abundant evidence that COVID-19 compelled humanity to perform on multiple fronts. Several ethical obstacles have been overcome in medicine to enable the rapid manufacture of vaccinations. Significant lessons about the application and utilization of resources have been learned in the field of education. In addition, there are ways to drastically lower the expense of schooling both individually and as a group. These resources can be used in other places to boost economies.

Furthermore, the proliferation of open universities is a testament to the great impacts of technology that is associated with the Covid-19 pandemic. It remains to be seen whether humanity can turn around the covid 19 situation to their advantage. Future opportunities abound in global climate change and food security. Therefore, the application of lessons drawn from the covid era can equip mankind better to prepare for future pandemic and to deal with infectious diseases as well as management of health services in the Low and Middle Income Countries.

 

Recommended further reading

1.      

1.     World Health Organization What Is a Pandemic? [(accessed on 5 January 2021)]. Available online: https://www.who.int/csr/disease/swineflu/frequently_asked_questions/pand...

2.      

1.     Centers for Disease Control and Prevention Are We Prepared? [(accessed on 25 April 2021)]; Available online: https://www.cdc.gov/flu/pandemic-resources/1918-commemoration/are-we-pre....

3.      

1.     World Health Organization WHO Coronavirus Disease (COVID-19) Dashboard. [(accessed on 31 January 2021)]. Available online: https://covid19.who.int/

4.      

1.     Kandel N., Chungong S., Omaar A., Xing J. Health security capacities in the context of COVID-19 outbreak: An analysis of International Health Regulations annual report data from 182 countries. Lancet. 2020;395:1047–1053. doi: 10.1016/S0140-6736(20)30553-5. - DOI - PMC - PubMed

5.      

1.     The World Bank The World by Income and Region. [(accessed on 5 January 2021)]. Available online: https://datatopics.worldbank.org/world-development-indicators/the-world-....

6.      

1.     Anjum F.R., Anam S., Rahman S.U. Novel Coronavirus disease 2019 (COVID-19): New challenges and new responsibilities in developing countries. Hum. Vaccines Immunother. 2020;16:2370–2372. doi: 10.1080/21645515.2020.1766939. - DOI - PMC - PubMed

7.      

1.     Tang Y.W., Schmitz J.E., Persing D.H., Stratton C.W. Laboratory Diagnosis of COVID-19: Current Issues and Challenges. J. Clin. Microbiol. 2020;58:e00512–e00520. doi: 10.1128/JCM.00512-20. - DOI - PMC - PubMed

8.      

1.     The COVID Tracking Project Totals for the US. [(accessed on 26 April 2021)]. Available online: https://covidtracking.com/data/national.

9.      

1.     Monjur M.R., Hassan M.Z. Early Phases of COVID-19 management in a low-income country: Bangladesh. Infect. Control Hosp. Epidemiol. 2020;41:1116–1117. doi: 10.1017/ice.2020.147. - DOI - PMC - PubMed

10.  

1.     Siow W.T., Liew M.F., Shrestha B.R., Muchtar F., See K.C. Managing COVID-19 in resource-limited settings: Critical care considerations. Crit. Care. 2020;24:167. doi: 10.1186/s13054-020-02890-x. - DOI - PMC - PubMed

11.  

1.     Rouzier V., Liautaud B., Deschamps M.M. Facing the Monster in Haiti. N. Engl. J. Med. 2020;383:e4. doi: 10.1056/NEJMc2021362. - DOI - PMC - PubMed

12.  

1.     World Health Organization WHO Guide for the Stepwise Laboratory Improvement Process Towards Accreditation in the African Region (with Checklist) [(accessed on 5 January 2021)]. Available online: https://www.who.int/tb/laboratory/afro-slipta-checklist-guidance.pdf.

13.  

1.     Quaresima V., Naldini M.M., Cirillo D.M. The prospects for the SARS-CoV-2 pandemic in Africa. EMBO Mol. Med. 2020;12:e12488. doi: 10.15252/emmm.202012488. - DOI - PMC - PubMed

14.  

1.     Centers for Disease Control and Prevention A New Tool to Diagnose Tuberculosis: The Xpert MTB/RIF Assay. [(accessed on 5 January 2021)]; Available online: https://www.cdc.gov/tb/publications/factsheets/pdf/xpertmtb-rifassayfact....

15.  

1.     Rakotosamimanana N., Randrianirina F., Randremanana R., Raherison M.S., Rasolofo V., Solofomalala G.D., Spiegel A., Heraud J.-M. GeneXpert for the diagnosis of COVID-19 in LMICs. Lancet Glob. Health. 2020;8:e1457–e1458. doi: 10.1016/S2214-109X(20)30428-9. - DOI - PMC - PubMed

16.  

1.     Lai C.C., Shih T.P., Ko W.C., Tang H.J., Hsueh P.R. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int. J. Antimicrob. Agents. 2020;55:105924. doi: 10.1016/j.ijantimicag.2020.105924. - DOI - PMC - PubMed

17.  

1.     Krishnakumar B., Rana S. COVID 19 in INDIA: Strategies to combat from combination threat of life and livelihood. J. Microbiol. Immunol. Infect. 2020;53:389–391. doi: 10.1016/j.jmii.2020.03.024. - DOI - PMC - PubMed

18.  

1.     Wang M.-W., Zhou M.-Y., Ji G.-H., Ye L., Cheng Y.-R., Feng Z.-H., Chen J. Mask crisis during the COVID-19 outbreak. Eur. Rev. Med. Pharmacol. Sci. 2020;24:3397–3399. - PubMed

19.  

1.     Sudhir A., Mor N. A primary care alternative to a hospital-based approach to COVID-19 in India. J. Glob. Health. 2020;10:020346. doi: 10.7189/jogh.10.020346. - DOI - PMC - PubMed

20.  

1.     World Health Organization Algorithm for COVID-19 Triage and Referral Patient Triage and Referral for Resource-Limited Settings during Community Transmission. [(accessed on 5 January 2021)]. Available online: https://apps.who.int/iris/bitstream/handle/10665/331915/COVID-19-algorit....

21.  

1.     Joebges S., Biller-Andorno N. Ethics guidelines on COVID-19 triage—An emerging international consensus. Crit. Care. 2020;24:201. doi: 10.1186/s13054-020-02927-1. - DOI - PMC - PubMed

22.  

1.     Barros L.M., Pigoga J.L., Chea S., Hansoti B., Hirner S., Papali A., Rudd K.E., Schultz M.J., Hynes E.J.C. Pragmatic Recommendations for Identification and Triage of Patients with COVID-19 Disease in Low- and Middle-Income Countries. Am. J. Trop. Med. Hyg. 2021;104:3–11. doi: 10.4269/ajtmh.20-1064. - DOI - PMC - PubMed

23.  

1.     Ayebare R.R., Flick R., Okware S., Bodo B., Lamorde M. Adoption of COVID-19 triage strategies for low-income settings. Lancet Respir. Med. 2020;8:e22. doi: 10.1016/S2213-2600(20)30114-4. - DOI - PMC - PubMed

24.  

1.     Nayan N., Kumar M.K., Nair R.K., Manral I., Ghosh S., Bhalla S., Singh J., Monga A., Afzal M., Kapoor R. Clinical Triaging in Cough Clinic Alleviates COVID-19 Overload in Emergency Department in India. SN Compr. Clin. Med. 2021;3:22–27. doi: 10.1007/s42399-020-00705-2. - DOI - PMC - PubMed

25.  

1.     Atreya A., Nepal B. Covid-19 pandemic and Nepal. Med. Leg. J. 2020;88:102–103. doi: 10.1177/0025817220923690. - DOI - PubMed

26.  

1.     Harris C., Carson G., Baillie J.K., Horby P., Nair H. An evidence-based framework for priority clinical research questions for COVID-19. J. Glob. Health. 2020;10:011001. doi: 10.7189/jogh.10.011001. - DOI - PMC - PubMed

27.  

1.     World Health Organization World Health Statistics 2019: Monitoring Health for the SDGs, Sustainable Development Goals. [(accessed on 5 January 2021)]. Available online: https://apps.who.int/iris/handle/10665/324835.

28.  

1.     Murthy S., Leligdowicz A., Adhikari N.K. Intensive care unit capacity in low-income countries: A systematic review. PLoS ONE. 2015;10:e0116949. doi: 10.1371/journal.pone.0116949. - DOI - PMC - PubMed

29.  

1.     Salluh J.I.F., Lisboa T., Bozza F.A. Challenges for the care delivery for critically ill COVID-19 patients in developing countries: The Brazilian perspective. Crit. Care. 2020;24:593. doi: 10.1186/s13054-020-03278-7. - DOI - PMC - PubMed

30.  

1.     Marson F.A.L., Ortega M.M. COVID-19 in Brazil. Pulmonology. 2020;26:241–244. doi: 10.1016/j.pulmoe.2020.04.008. - DOI - PMC - PubMed

31.  

1.     Federal Republic of Nigeria National Strategy for the Scale-Up of Medical Oxygen in Health Facilities. [(accessed on 5 January 2021)]; Available online: https://www.health.gov.ng/doc/National%20Startegy%20for%20Scale-up%20of%....

32.  

1.     Republic of Uganda Ministry of Health Scale up of Medical Oxygen in Higher Level Facilities Implementation Plan. [(accessed on 5 January 2021)]. Available online: http://library.health.go.ug/sites/default/files/resources/MOH%20National....

33.  

1.     World Health Organization Severe Acute Respiratory Infections Treatment Center: Practical Manual to set up and Manage a SARI Treatment Center and SARI Screening Facility in Health Care Facilities. [(accessed on 5 January 2021)]. Available online: https://apps.who.int/iris/handle/10665/331603.

34.  

1.     Sansone P., Giaccari L.G., Aurilio C., Coppolino F., Esposito V., Fiore M., Paladini A., Passavanti M.B., Pota V., Pace M.C. Post-Infectious Guillain–Barré Syndrome Related to SARS-CoV-2 Infection: A Systematic Review. Life. 2021;11:167. doi: 10.3390/life11020167. - DOI - PMC - PubMed

35.  

1.     Warren T.K., Jordan R., Lo M.K., Ray A.S., Mackman R.L., Soloveva V., Siegel D., Perron M., Bannister R., Hui H.C., et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature. 2016;531:381–385. doi: 10.1038/nature17180. - DOI - PMC - PubMed

36.  

1.     Cvetkovic R.S., Goa K.L. Lopinavir/ritonavir: A review of its use in the management of HIV infection. Drugs. 2003;63:769–802. doi: 10.2165/00003495-200363080-00004. - DOI - PubMed

37.  

1.     Lei Z.-N., Wu Z.-X., Dong S., Yang D.-H., Zhang L., Ke Z., Zou C., Chen Z.-S. Chloroquine and hydroxychloroquine in the treatment of malaria and repurposing in treating COVID-19. Pharmacol. Ther. 2020;216:107672. doi: 10.1016/j.pharmthera.2020.107672. - DOI - PMC - PubMed

38.  

1.     National Institutes of Health COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. [(accessed on 5 January 2021)]; Available online: https://files.covid19treatmentguidelines.nih.gov/guidelines/covid19treat....

39.  

1.     FDA Veklury (Remdesivir) EUA Letter of Approval. [(accessed on 5 January 2021)]; Available online: https://www.fda.gov/media/137564/download.

40.  

1.     FDA Veklury (Remdesivir) EUA Letter of Authorization. [(accessed on 5 January 2021)]; Available online: https://www.fda.gov/media/143188/download.

41.  

1.     Dagens A., Sigfrid L., Cai E., Lipworth S., Cheung V., Harris E., Bannister P., Rigby I., Horby P. Scope, quality, and inclusivity of clinical guidelines produced early in the COVID-19 pandemic: Rapid review. BMJ. 2020;369:m1936. doi: 10.1136/bmj.m1936. - DOI - PMC - PubMed

42.  

1.     Liu X., Wang X.J. Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines. J. Genet. Genom. 2020;47:119–121. doi: 10.1016/j.jgg.2020.02.001. - DOI - PMC - PubMed

43.  

1.     Chen F., Chan K.H., Jiang Y., Kao R.Y.T., Lu H.T., Fan K.W., Cheng V.C.C., Tsui W.H.W., Hung I.F.N., Lee T.S.W., et al. In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds. J. Clin. Virol. 2004;31:69–75. doi: 10.1016/j.jcv.2004.03.003. - DOI - PMC - PubMed

44.  

1.     Yao X., Ye F., Zhang M., Cui C., Huang B., Niu P., Liu X., Zhao L., Dong E., Song C., et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Clin. Infect. Dis. 2020;71:732–739. doi: 10.1093/cid/ciaa237. - DOI - PMC - PubMed

45.  

1.     Saha B.K., Bonnier A., Chong W. Antimalarials as Antivirals for COVID-19: Believe it or Not! Am. J. Med. Sci. 2020;360:618–630. doi: 10.1016/j.amjms.2020.08.019. - DOI - PMC - PubMed

46.  

1.     Rochwerg B., Siemieniuk R.A., Agoritsas T., Lamontagne F., Askie L., Lytvyn L., Agarwal A., Leo Y.-S., Macdonald H., Zeng L., et al. A living WHO guideline on drugs for COVID-19. BMJ. 2020;370:m3379. Erratum in 2020, 371, m4475. - PubMed

47.  

1.     Hill A., Wang J., Levi J., Heath K., Fortunak J. Minimum costs to manufacture new treatments for COVID-19. J. Virus. Erad. 2020;6:61–69. doi: 10.1016/S2055-6640(20)30018-2. - DOI - PMC - PubMed

48.  

1.     The Global Fund. [(accessed on 5 January 2021)]. Available online: https://www.theglobalfund.org/en/

49.  

1.     FDA President’s Emergency Plan for AIDS Relief (PEPFAR) [(accessed on 5 January 2021)]; Available online: https://www.fda.gov/international-programs/presidents-emergency-plan-aid....

50.  

1.     Meara J.G., Leather A.J.M., Hagander L., Alkire B.C., Alonso N., Ameh E.A., Bickler S.W., Conteh L., Dare A.J., Davies J., et al. Global Surgery 2030: Evidence and solutions for achieving health, welfare, and economic development. Lancet. 2015;386:569–624. doi: 10.1016/S0140-6736(15)60160-X. - DOI - PubMed

51.  

1.     Bibiano-Guillen C., Arias-Arcos B., Collado-Escudero C., Mir-Montero M., Corella-Montoya F., Torres-Macho J., Buendía-Garcia M., Larrainzar-Garijo R. Adapted Diving Mask (ADM) device as respiratory support with oxygen output during COVID-19 pandemic. Am. J. Emerg. Med. 2021;39:42–47. doi: 10.1016/j.ajem.2020.10.043. - DOI - PMC - PubMed

52.  

1.     Dondorp A.M., Hayat M., Aryal D., Beane A., Schultz M.J. Respiratory Support in COVID-19 Patients, with a Focus on Resource-Limited Settings. Am. J. Trop. Med. Hyg. 2020;102:1191–1197. doi: 10.4269/ajtmh.20-0283. - DOI - PMC - PubMed

53.  

1.     World Health Organization Oxygen Sources and Distribution for COVID-19 Treatment Centres. [(accessed on 5 January 2021)]. Available online: https://www.who.int/publications-detail/oxygensources-and-distribution-f....

54.  

1.     So A.D., Woo J. Reserving coronavirus disease 2019 vaccines for global access: Cross sectional analysis. BMJ. 2020;371:m4750. doi: 10.1136/bmj.m4750. - DOI - PMC - PubMed

55.  

1.     McAdams D., McDade K.K., Ogbuoji O., Johnson M., Dixit S., Yamey G. Incentivising wealthy nations to participate in the COVID-19 Vaccine Global Access Facility (COVAX): A game theory perspective. BMJ Glob. Health. 2020;5:e003627. doi: 10.1136/bmjgh-2020-003627. - DOI - PMC - PubMed

56.  

1.     Lie R.K., Miller F.G. Allocating a COVID-19 Vaccine: Balancing National and International Responsibilities. Milbank Q. 2020;99:450–466. doi: 10.1111/1468-0009.12494. - DOI - PMC - PubMed